Supplementary Figures from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Le résumé fourni par la source

Supplementary Figure 1 ARID1A mutations in the panel of OCCC tumour cell line models with corresponding protein expression. Supplementary Figure 2 Un-cropped western blots from main and supplementary figures. Supplementary Figure 3 ARID1A selective effects from the high throughput drug screen. Supplementary Figure 4 Inhibitors of the PI3K/mTOR signalling pathway in the panel of OCCC cell lines and ARID1A selectivity. Supplementary Figure 5 Dasatinib is a synthetic lethal drug in ARID1A mutant OCCC tumour cell line models - see also Figure 2. Supplementary Figure 6 Dasatinib sensitivity in ARID1A mutant isogenic HCT116 colorectal tumour cell line model. Supplementary Figure 7 Dasatinib siRNA screen results. Supplementary Figure 8 Apoptosis assay in four OCCC cell line models, see also Figure 4. Supplementary Figure 9 Dasatinib sensitivity in ARID1A mutant OCCC is dependent upon G1/S checkpoint effectors, see also Figure 5. Supplementary Figure 10 Determining the optimal method of dasatinib delivery in vivo.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.